It’s been a humbling first half of the year for health tech companies.
Previously abundant venture funding for health companies continues to shrink, and a growing number face unprecedented legal and regulatory challenges. Virtual care pioneer Teladoc, hobbled by the unprofitable acquisition of Livongo, is being sued for misleading investors. Cerebral, an online company that virtually prescribed controlled substances including Adderall, is under dual investigations by the Federal Trade Commission and the Drug Enforcement Agency for its marketing and prescribing practices.
Create a display name to comment
This name will appear with your comment
